CY1112570T1 - Θεραπεια καρκινων με μετασταση - Google Patents
Θεραπεια καρκινων με μεταστασηInfo
- Publication number
- CY1112570T1 CY1112570T1 CY20111101216T CY111101216T CY1112570T1 CY 1112570 T1 CY1112570 T1 CY 1112570T1 CY 20111101216 T CY20111101216 T CY 20111101216T CY 111101216 T CY111101216 T CY 111101216T CY 1112570 T1 CY1112570 T1 CY 1112570T1
- Authority
- CY
- Cyprus
- Prior art keywords
- cancer treatment
- compound
- transitional cancer
- tautomer
- pharmaceutically acceptable
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000037819 metastatic cancer Diseases 0.000 abstract 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Μέθοδοι για τη θεραπεία του μεταστατικού καρκίνου όπως όγκοι με μετάσταση περιλαμβάνουν τη χορήγηση σε ένα υποκείμενο που το έχει ανάγκη, μιας αποτελεσματικής ποσότητας μιας ένωσης της Δομής I, ενός ταυτομερούς της ένωσης, ενός φαρμακευτικώς αποδεκτού άλατος της ένωσης, ενός φαρμακευτικώς αποδεκτού άλατος του ταυτομερούς, ή ενός μείγματος αυτών. Η ένωση, το ταυτομερές, το άλας της ένωσης, το άλας του ταυτομερούς, ή μείγμα αυτών μπορούν να χρησιμοποιηθούν για την παρασκευή φαρμάκων για τη θεραπεία του μεταστατικού καρκίνου. Η μεταβλητή Α έχει τις τιμές που ορίζονται στο παρόν.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US64756805P | 2005-01-27 | 2005-01-27 | |
US66924505P | 2005-04-06 | 2005-04-06 | |
US72205305P | 2005-09-29 | 2005-09-29 | |
EP06733986A EP1845990B1 (en) | 2005-01-27 | 2006-01-27 | Treatment of metastasized tumors |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1112570T1 true CY1112570T1 (el) | 2016-02-10 |
Family
ID=36741085
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20111101216T CY1112570T1 (el) | 2005-01-27 | 2011-12-06 | Θεραπεια καρκινων με μετασταση |
Country Status (23)
Country | Link |
---|---|
US (2) | US20060183750A1 (el) |
EP (2) | EP2301546B1 (el) |
JP (2) | JP5371246B2 (el) |
KR (1) | KR101387985B1 (el) |
CN (1) | CN103893181A (el) |
AT (1) | ATE526025T1 (el) |
AU (1) | AU2006208012B2 (el) |
BR (1) | BRPI0607285A2 (el) |
CA (1) | CA2596084A1 (el) |
CY (1) | CY1112570T1 (el) |
DK (1) | DK1845990T3 (el) |
ES (2) | ES2374570T3 (el) |
HK (1) | HK1155664A1 (el) |
IL (1) | IL184866A0 (el) |
MA (1) | MA29266B1 (el) |
MX (1) | MX2007009099A (el) |
NO (1) | NO20074360L (el) |
PL (2) | PL1845990T3 (el) |
PT (2) | PT1845990E (el) |
SG (1) | SG173317A1 (el) |
SI (1) | SI2301546T1 (el) |
TN (1) | TNSN07294A1 (el) |
WO (1) | WO2006081445A2 (el) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2334641T3 (es) | 2000-09-01 | 2010-03-15 | Novartis Vaccines And Diagnostics, Inc. | Derivados aza heterociclicos y su uso terapeutico. |
EP1539754A4 (en) | 2002-08-23 | 2009-02-25 | Novartis Vaccines & Diagnostic | BENZIMIDAZOLE QUINOLINONES AND USES THEREOF |
ES2440799T3 (es) * | 2005-05-13 | 2014-01-30 | Novartis Ag | Métodos para tratar cáncer resistente a los fármacos |
RU2425041C2 (ru) * | 2005-05-23 | 2011-07-27 | Новартис Аг | Кристаллические и другие формы солей, образованных из молочной кислоты и 4-амино-5-фтор-3-[6-(4-метилпиперазин-1-ил)-1н-бензимидазол-2-ил]-1н-хинолин-2-она |
AR070924A1 (es) * | 2008-03-19 | 2010-05-12 | Novartis Ag | Formas cristalinas y dos formas solvatadas de sales del acido lactico de 4- amino -5- fluoro-3-(5-(4-metilpiperazin-1-il ) -1h- bencimidazol-2-il) quinolin -2-(1h) - ona |
WO2010135534A2 (en) * | 2009-05-20 | 2010-11-25 | Children's Medical Center Corporation | Compositions for the treatment of metastatic cancer and methods of use thereof |
CA2793779A1 (en) | 2010-04-16 | 2011-10-20 | Novartis Ag | Organic compound for use in the treatment of liver cancer |
KR20140023358A (ko) * | 2011-05-19 | 2014-02-26 | 노파르티스 아게 | 선양 낭성 암종의 치료에 사용하기 위한 4-아미노-5-플루오로-3-[6-(4-메틸피페라진-1-일)-1h-벤즈이미다졸-2-일]-1h-퀴놀린-2-온 |
CA2861377A1 (en) * | 2012-01-31 | 2013-08-08 | Novartis Ag | Combination of a rtk inhibitor with an anti - estrogen and use thereof for the treatment of cancer |
JP6990228B2 (ja) * | 2016-07-14 | 2022-01-13 | ブリストル-マイヤーズ スクイブ カンパニー | 二環式ヘテロアリール置換の化合物 |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3663606A (en) * | 1966-06-21 | 1972-05-16 | Mitsui Toatsu Chemicals | Organic imino-compounds |
DE2363459A1 (de) | 1973-12-20 | 1975-06-26 | Basf Ag | Neue fluoreszierende chinolinverbindungen |
US4659657A (en) * | 1982-12-24 | 1987-04-21 | Bayer Aktiengesellschaft | Chromogenic and fluorogenic esters for photometric or fluorimetric determination of phosphatases or sulphatases |
US5073492A (en) * | 1987-01-09 | 1991-12-17 | The Johns Hopkins University | Synergistic composition for endothelial cell growth |
JPH0699497B2 (ja) | 1987-04-16 | 1994-12-07 | 富士写真フイルム株式会社 | 光重合性組成物 |
DE3932953A1 (de) * | 1989-10-03 | 1991-04-11 | Boehringer Mannheim Gmbh | Neue 2-bicyclo-benzimidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
GB9108547D0 (en) | 1991-04-22 | 1991-06-05 | Fujisawa Pharmaceutical Co | Quinoline derivatives |
US5480883A (en) * | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
USRE37650E1 (en) * | 1991-05-10 | 2002-04-09 | Aventis Pharmacetical Products, Inc. | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
US5710158A (en) * | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
US5856115A (en) * | 1991-05-24 | 1999-01-05 | Fred Hutchinson Cancer Research Center | Assay for identification therapeutic agents |
PT627940E (pt) * | 1992-03-05 | 2003-07-31 | Univ Texas | Utilizacao de imunoconjugados para o diagnostico e/ou terapia de tumores vascularizados |
JP3142378B2 (ja) | 1992-06-22 | 2001-03-07 | ティーディーケイ株式会社 | 有機el素子 |
US5981569A (en) * | 1992-11-13 | 1999-11-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Substituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease |
US5792771A (en) * | 1992-11-13 | 1998-08-11 | Sugen, Inc. | Quinazoline compounds and compositions thereof for the treatment of disease |
US5763441A (en) * | 1992-11-13 | 1998-06-09 | Sugen, Inc. | Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis |
JPH0743896A (ja) | 1993-07-28 | 1995-02-14 | Toyobo Co Ltd | 光重合性組成物 |
JPH0829973A (ja) | 1994-07-11 | 1996-02-02 | Toyobo Co Ltd | 光重合性組成物 |
JP3441246B2 (ja) * | 1995-06-07 | 2003-08-25 | 富士写真フイルム株式会社 | 光重合性組成物 |
GB9624482D0 (en) * | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
DE19610723A1 (de) | 1996-03-19 | 1997-09-25 | Bayer Ag | Elektrolumineszierende Anordnungen unter Verwendung von Blendsystemen |
US5942385A (en) * | 1996-03-21 | 1999-08-24 | Sugen, Inc. | Method for molecular diagnosis of tumor angiogenesis and metastasis |
EP2223920A3 (en) * | 1996-06-19 | 2011-09-28 | Aventis Pharma Limited | Substituted azabicyclic compounds |
JP2000514048A (ja) | 1996-06-20 | 2000-10-24 | ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム | 薬理学的活性調製物を提供するための化合物および方法ならびにそれらの使用 |
US6111110A (en) * | 1996-10-30 | 2000-08-29 | Eli Lilly And Company | Synthesis of benzo[f]quinolinones |
EP1226136B1 (en) | 1999-10-19 | 2004-12-29 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
JP2003512353A (ja) | 1999-10-19 | 2003-04-02 | メルク エンド カムパニー インコーポレーテッド | チロシンキナーゼ阻害剤 |
US6313138B1 (en) * | 2000-02-25 | 2001-11-06 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
AU778417B2 (en) | 2000-02-25 | 2004-12-02 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
US6420382B2 (en) | 2000-02-25 | 2002-07-16 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
ES2334641T3 (es) | 2000-09-01 | 2010-03-15 | Novartis Vaccines And Diagnostics, Inc. | Derivados aza heterociclicos y su uso terapeutico. |
AU2001288432A1 (en) * | 2000-09-01 | 2002-03-22 | Icos Corporation | Materials and methods to potentiate cancer treatment |
SG174632A1 (en) * | 2000-09-11 | 2011-10-28 | Novartis Vaccines & Diagnostic | Quinolinone derivatives |
US20030028018A1 (en) | 2000-09-11 | 2003-02-06 | Chiron Coporation | Quinolinone derivatives |
US7064215B2 (en) * | 2001-07-03 | 2006-06-20 | Chiron Corporation | Indazole benzimidazole compounds |
US7825132B2 (en) * | 2002-08-23 | 2010-11-02 | Novartis Vaccines And Diagnostics, Inc. | Inhibition of FGFR3 and treatment of multiple myeloma |
EP1539754A4 (en) * | 2002-08-23 | 2009-02-25 | Novartis Vaccines & Diagnostic | BENZIMIDAZOLE QUINOLINONES AND USES THEREOF |
KR20050075005A (ko) | 2002-11-13 | 2005-07-19 | 카이론 코포레이션 | 암을 치료하는 방법 및 관련 방법 |
US6774327B1 (en) * | 2003-09-24 | 2004-08-10 | Agilent Technologies, Inc. | Hermetic seals for electronic components |
WO2005046589A2 (en) * | 2003-11-07 | 2005-05-26 | Chiron Corporation | Pharmaceutically acceptable salts of quinolinone compounds having improved pharmaceutical properties |
BRPI0507891A (pt) * | 2004-02-20 | 2007-07-24 | Chiron Corp | modulação dos processos inflamatório e metastático |
US20060261307A1 (en) * | 2005-05-18 | 2006-11-23 | Black D J | Water Activated Organic Scavenger |
KR102639757B1 (ko) | 2017-01-09 | 2024-02-23 | 엘지이노텍 주식회사 | 카메라 모듈 및 이를 포함하는 광학기기 |
-
2006
- 2006-01-27 EP EP10186757.0A patent/EP2301546B1/en not_active Revoked
- 2006-01-27 MX MX2007009099A patent/MX2007009099A/es not_active Application Discontinuation
- 2006-01-27 AT AT06733986T patent/ATE526025T1/de active
- 2006-01-27 SI SI200631858T patent/SI2301546T1/sl unknown
- 2006-01-27 DK DK06733986.1T patent/DK1845990T3/da active
- 2006-01-27 US US11/342,257 patent/US20060183750A1/en not_active Abandoned
- 2006-01-27 PT PT06733986T patent/PT1845990E/pt unknown
- 2006-01-27 BR BRPI0607285-2A patent/BRPI0607285A2/pt not_active IP Right Cessation
- 2006-01-27 EP EP06733986A patent/EP1845990B1/en not_active Not-in-force
- 2006-01-27 KR KR1020077019428A patent/KR101387985B1/ko not_active IP Right Cessation
- 2006-01-27 SG SG2011046166A patent/SG173317A1/en unknown
- 2006-01-27 CA CA002596084A patent/CA2596084A1/en not_active Abandoned
- 2006-01-27 AU AU2006208012A patent/AU2006208012B2/en not_active Ceased
- 2006-01-27 CN CN201410121175.8A patent/CN103893181A/zh active Pending
- 2006-01-27 PT PT101867570T patent/PT2301546E/pt unknown
- 2006-01-27 ES ES06733986T patent/ES2374570T3/es active Active
- 2006-01-27 JP JP2007553278A patent/JP5371246B2/ja not_active Expired - Fee Related
- 2006-01-27 PL PL06733986T patent/PL1845990T3/pl unknown
- 2006-01-27 WO PCT/US2006/002979 patent/WO2006081445A2/en active Application Filing
- 2006-01-27 PL PL10186757T patent/PL2301546T3/pl unknown
- 2006-01-27 ES ES10186757.0T patent/ES2525670T3/es active Active
-
2007
- 2007-07-26 IL IL184866A patent/IL184866A0/en unknown
- 2007-07-27 TN TNP2007000294A patent/TNSN07294A1/en unknown
- 2007-08-23 MA MA30162A patent/MA29266B1/fr unknown
- 2007-08-27 NO NO20074360A patent/NO20074360L/no not_active Application Discontinuation
-
2009
- 2009-12-31 US US12/650,725 patent/US20100173873A1/en not_active Abandoned
-
2011
- 2011-09-22 HK HK11110024A patent/HK1155664A1/xx not_active IP Right Cessation
- 2011-12-06 CY CY20111101216T patent/CY1112570T1/el unknown
-
2013
- 2013-06-20 JP JP2013129277A patent/JP2013177464A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1112570T1 (el) | Θεραπεια καρκινων με μετασταση | |
NO2017019I2 (no) | Enzalutamid eller et farmasøytisk akseptabelt salt derav | |
ZA200706530B (en) | Meleimide derivatives, pharmaceutical compositions and methods for treatment of cancer | |
NO20091661L (no) | Anvendelse av pegylert IL-10 for a behandle kreft | |
EA201001143A1 (ru) | Активаторы прокаспаз "исполнителей" 3, 6 и 7 | |
DE602006014579D1 (de) | Heteroalkylgebundene pyrimidinderivate | |
EA200801428A1 (ru) | Производные пиридиазинона для лечения опухолей | |
TW200640883A (en) | Compounds for the treatment of proliferative disorders | |
MX2007002398A (es) | Nuevas composiciones farmaceuticas para el tratamiento de cancer. | |
EA200870415A1 (ru) | Хиназолины для ингибирования pdk 1 | |
WO2005110994A3 (en) | Substituted pyrazolyl urea derivatives useful in the treatment of cancer | |
TW200716570A (en) | Compounds for the treatment of proliferative disorders | |
CR8696A (es) | Beta-carbolinas utiles para tratar enfermedades inflamatorias | |
WO2005070043A3 (en) | Methods for treating non-melanoma cancers with paba | |
MX2010003365A (es) | Derivados de tiazol para el tratamiento de cancer. | |
WO2006044975A3 (en) | Compositions and their use as anti-tumor agents | |
MX2009009574A (es) | Tratamiento de melanoma. | |
WO2005085188A3 (en) | Compounds and methods for anti-tumor therapy | |
WO2008011113A3 (en) | Thiadiazolidinone derivatives | |
TW200735866A (en) | Compounds for the treatment of proliferative disorders | |
ATE435647T1 (de) | Rutheniumkomplexe zur krebsbehandlung | |
EA200971067A1 (ru) | Триазолиламинопиримидиновые соединения | |
GB0305928D0 (en) | Organic compounds | |
TW200706174A (en) | Indole compounds | |
TW200706536A (en) | Indole compounds |